Table 1.
Summary of the three study characteristics included in the review: CIN2, CIN3, and ICC
| No. | Study ID (author and year) | Study reference number | Country | Study design | Index test | Reference method | Sample size | Median age | CIN2+, n (%) | ICC, n (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Salazar‐Piña (2016) 20 | d1 | Mexico | Diagnostic test accuracy study | HPV16 E4 and E7 immunoenzymatic assay (slot‐blot) | Histopathology | 485 | 40.0 | 106 (29.9) | 15 (3.1) |
| 2 | Jin (2018) 34 | d2 | South Korea | Case–control study | HPV E6 and E7 (ELISA) | Cytology | 249 | 44.3 | 144 (57.8) | ‐ |
| 3 | Combes (2014) 35 | d3 | Algeria and India | Case–control study | HPV16 L1, E1,E2, E4, E6, and E7 (multiplex HPV serology immunofluorescent assay) | Cytology | 816 | 50.9 | ‐ | 307 (37.6) |
Abbreviations: CIN, cervical intraepithelial neoplasia; ELISA, enzyme‐linked immunosorbent assay; HPV, human papillomavirus; ICC, invasive cervical cancer.